| Name | Title | Contact Details |
|---|---|---|
Robert Truckenmiller |
Chief Executive Officer | Profile |
Rob Macrae |
General Counsel, US Commercial, at GSK | Profile |
Sarah Clements |
Senior Vice President and Head of Legal - Group Transformation and Separation | Profile |
Michael Riordan |
Assistant General Counsel | Profile |
Jennean Endres |
Vice President Legal, US Respiratory, US Rx Contracting, Digital Channels and Operations | Profile |
Vigil Neuroscience is the world`s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain`s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.
Esperance Pharmaceuticals, Inc. is developing a new class of targeted oncology products that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cancer cell surface. The novel product candidates destroy dividing and non-dividing cancer cells including those known to be resistant to chemotherapeutics.
Ferring Research Institute is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and over the counter products for the North American market. Our vision is to deliver high quality products at affordable prices by leveraging global partnerships with the best FDA approved manufacturing facilities across the world.
Syntonix Pharmaceuticals, Inc is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.